Precipio Strengthens Patent Portfolio with Expanded Kit Claims for its Liquid Biopsy Enabling DNA Mutation Enrichment Technology

Medical Device Investing

Specialty cancer diagnostics company Precipio (NASDAQ:PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT WITH REFERENCE BLOCKING SEQUENCE, to Harvard-affiliated Dana–Farber Cancer Institute, the licensor of Precipio’s ICE-COLD PCR DNA enrichment platform, and to Precipio’s scientific advisory board member Dr. Gerassimos (Mike) Makrigiorgos. As quoted in the press release: While previous patents issued …

Specialty cancer diagnostics company Precipio (NASDAQ:PRPO), today announced the award of US patent No. 9,957,556 entitled FULL COLD-PCR ENRICHMENT WITH REFERENCE BLOCKING SEQUENCE, to Harvard-affiliated Dana –Farber Cancer Institute, the licensor of Precipio’s ICE-COLD PCR DNA enrichment platform, and to Precipio’s scientific advisory board member Dr. Gerassimos (Mike) Makrigiorgos.

As quoted in the press release:

While previous patents issued on ICE COLD-PCR related to process methods, the new patent protects the use and application of kits containing reagents essential to performing ICE-COLD PCR.
The patent portfolio related to ICE COLD-PCR and COLD-PCR now includes 17 separate patents.
The newly issued patent further strengthens the global patent portfolio surrounding ICE COLD-PCR and the use of ICP liquid biopsy technology in mutation enrichment kits with nine additional patent claims.
The ICP patent portfolio will enable Precipio to continue advances in the ICP kit product portfolio and provide customers consistent quality and cost effective liquid biopsy technology for tumor analysis, therapeutic monitoring and recurrence monitoring.

Click here to read the full press release.

dana-farber cancer institute nasdaq:prpo precipio Medical Device Investing